Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: A preliminary report

European Journal of Haematology

Volumn 72, Issue 2, 2004, Pages 113-120

  Clavio, Marino ^a   Nobili, Flavio ^a   Balleari, Enrico ^a   Girtler, Nicola ^a   Ballerini, Filippo ^a   Vitali, Paolo ^a   Rosati, Paola ^a   Venturino, Claudia ^a   Varaldo, Riccardo ^a   Gobbi, Marco ^a,b   Ghio, Riccardo ^a   Rodriguez, Guido ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Brain function; FACT An; Low risk MDS; Quality of life; rHuEpo

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; BRAIN; BRAIN BLOOD FLOW; BRAIN DYSFUNCTION; BRAIN FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOPPLER ECHOGRAPHY; DOSE RESPONSE; DRUG EFFECT; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; NEUROPHYSIOLOGY; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SELF REPORT; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN; ELECTROENCEPHALOGRAPHY; ERYTHROPOIETIN, RECOMBINANT; FATIGUE; HUMANS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUROPSYCHOLOGICAL TESTS; PATIENT SELECTION; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 10744230996     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0902-4441.2003.00183.x     Document Type: Article

References (46)

1. HEANEY ML, GOLDS DW. Myelodisplasia. NEJM 1999;340:1649-1654.
2. MORROW GR, ANDREWS PL, HICKOK JT, ROSCOE JA, MATTESON S. Fatigue associated with cancer and its treatment. Support Care Cancer 2002;10:389-398.
3. CELLA D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998;25(Suppl. 17):43-46.
4. ALESSANDRINO EP, AMADORI S, BAROSI G, et al. Evidence-and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002;87: 1286-1306.
5. CAZZOLA M, ANDERSON JE, GANSER A, HELLSTROM-LINDBERG E. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica 1998;83:910-935.
6. CAZZOLA M, PONCHIO L, BEGUIN Y, ROSTI V, BERGAMASCHI G, LIBERATO NL, FREGONI V, NALLI G, BAROSI G, ASCARI E. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/ II clinical trial. Blood 1992;79:29-37.
7. HELLSTROM-LINDBERG E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89:67-71.
8. REMACHA AF, ARRIZABALAGA B, VILLEGAS A, MANTEIGA R, CALVO T, JULIA A. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica 1999;84:1058-1064.
9. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomized double blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 1998;103:1070-1074.
10. TERPOS E, MOUGIOU A, KOURAKLIS A, et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 2002;118:174-180.
11. DEMETRI GD, KRIS M, WADE J, DEGOS L, CELLA D for the Procrit Study Group. Quality of life benfit in chemotherapy patients treated with epoetin alpha is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412-3425.
12. CASADEVALL N, DURIEUX P, DUBOIS S, et al. Erythropoietin (rHuEpo) plus G-CSF in the treatment of anemia in myelodysplastic syndromes (MDS): results of a randomized trial with impact on quality of life and costs. Blood 2001;98(Suppl. 2):848a.
13. HELLSTROM-LINDBERG E, GULBRANDSEN N, LINDBERG G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120:1037-1046.
14. NISSENSON AR. Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life. Semin Nephrol 1989;9(Suppl. 2):25-31.
15. GRIMM G, STOCKENHUBER F, SCHNEEWEISS B, MADL C, ZEITLHOFER J, SCHNEIDER B. Improvement of brain function in hemodialysis patients treated with erythropoietin. Kidney Int 1990;38:480-486.
16. MARSH JT, BROWN WS, WOLCOTT D, CARR CR, HARPER R, SCHWEITZER SV, NISSENSON AR. rHuEPO treatment improves brain and cognitive function of anemic dyalisis patients. Kidney Int 1991;39:155-163.
17. TEMPLE R, DEARY IJ, WINNEY RJ. RhEpo improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis. Nephrol Dial Transplant 1995;10:1733-1738.
18. PICKETT JL, THEBERGE DC, BROWN WS, SCHWEITZER SU, NISSENSON AR. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999;33:1122-1130.
19. BRINES ML, GHEZZI P, KEENAN S, AGNELLO D, de LANEROLLE NC, CERAMI C, ITRI LM, CERAMI A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-10531.
20. CHESON BD, BENNETT JM, KANTARJIAN H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-3674.
21. CELLA D. The Functional Assessment of cancer Therapy-anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(Suppl. 2):13-19.
22. YELLEN SB, CELLA DF, WEBSTER K, BLENDOWSKI C, KAPLAN E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Symptom Manag 1997;13:63-74.
23. RUSSO G, LODI CA, URSINO M. Quantitative assessment of cerebral vascular reserve by means of transcranial Doppler ultrasound and rebreathing maneuver: bedside test and mathematical modeling. Neurol Sci 2000;21:292-302.
24. FOLSTEIN MF, FOLSTEIN SE, MCHUGH PR. 'Mini Mental State': a practical method for grading the cognitive state of patients for clinician. J Psychiatr Res 1975;12:189-198.
25. MASUR DM, FULD PA, BLAU AD, THAL LJ, LEVIN HS, ARONSON MK. Distinguishing normal and demented elderly with selective reminding test. J Clin Exp Neuropsychol 1989;11:615-630.
26. SPINNLER H, TOGNONI G. Standardizzazione e taratura italiana di test neuropsicologici. Ital J Neurol Sci 1987;6(Suppl. 8):1-120.
27. GIOVAGNOLI AR, DEL PESCE M, MASCHERONI S, SIMONCELLI M, LAIACONA M, CAPITANI E. Trail Making Test: normative values from 287 normal adults controls. Ital J Neurol Sci 1996;17:305-309.
28. RODRIGUEZ G, COPELLO F, VITALI P, PEREGO G, NOBILI F. EEG spectral profile to stage Alzheimer's disease. Clin Neurophysiol 1999;110:1831-1837.
29. PATRICK DL, GAGNON D, ZAGARI M. Assessment the clinical significance of changes in health-related quality of life (HRQOL) scores (abstract).QOL Res 2000;9:275.
30. ALOE SPIRITI MA for the Italian Fatigue-QoL/MDS Cooperative Group, Italy. Effects of 40,000 IU biweekly induction dose of epoetin alfa followed by 40, 000 IU once weekly in low-risk myelodysplastic syndrome patients (abstract). Blood 2002;100(Suppl. 1):790a.
31. MANTOVANI L, LENTINI G, HENTSCHEL B, WICKRAMANAYAKE PD, LOEFFLER M, DIEHL V, TESCH H. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 2000;109:367-375.
32. GLASPY J, BUKOWSKI R, STEINBERG D, TAYLOR C, TCHEKMEDYIAN S, VADHAN-RAJ S, for the procrit Study group. Impact of therapy with epoetin alfa on clinical outcomes in patients with non myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218-1234.
33. QUIRT I, ROBESON C, LAU CY, KOVACS M, BURDETTE-RADOUX S, DOLAN S, TANG SC, MCKENZIE M, COUTURE F, Canadian Eprex Oncology Study Group. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001;19:4126-4134.
34. LITTLEWOOD TJ, BAJETTA E, NORTIER JW, VERCAMMEN E, RAPOPORT Bfor the Epoetin Alfa Study Group. Effects of epoetin alpha on haematologic parameters and quality of life in cancer patients receiving non platinum chemotherapy: results of a randomized, double blind, placebo controlled trial. J Clin Oncol 2001;19:2865-2874.
35. MCCLEARY R, DICK MB, BUCKWALTER G, HENDERSON V, SHANKLE WR. Full-information models for multiple psychometric tests: annualised rates of change in normal aging and dementia. Alzheimer Dis Assoc Disord 1996;10:216-223.
36. HOFF AL, SAKUMA M, WIENEKE M, HORON R, KUSHNER M, DELISI LE. Longitudinal neuropsychological follow-up study of patients with first-episode schizofrenia. Am J Psychiatry 1999;156:1336-1341.
37. KONDACS A, SZABO M. Long-term intra-individual variability of the background EEG in normals. Clin Neurophysiol 1999;110:1708-1716.
38. DI PAOLO B, DI MARCO T, CAPPELLI P, SPISNI C, DEL ROSSO G, PALMIERI PF, EVANGELISTA M, ALBERTAZZI A. Electrophysiological aspects of nervous conduction in uremia. Clin Nephrol 1988;29:253-260.
39. FOX E, MCDOWALL J, NEALE TJ, MORRISON RB, HATFIELD PJ. Cognitive function and quality of life in end-stage renal failure. Ren Fail 1993;15:211-214.
40. WADE JPH, BROWN MM. Cerebral Blood flow in haematological disorders. In KNEZEVIC S, MAXIMILIAN VA, MULZIN Z, PROHOVNIK I, WADE J, Eds. Handbook of Regional Cerebral Blood Flow. Hillsdale, NY: Lawrence Elbaum, 1989:255-282.
41. NOBLE J, JONES JG, DAVIS EJ. Cognitive function during moderate hypoxaemia. Anaesth Intensive Care 1993;21:180-184.
42. GIACHELLI CM, JONO S, SHIOI A, NISHIZAWA Y, MORI K, MORII H. Vascular calcification and inorganic phosphate. Am J Kidney Dis 2001;38(Suppl. 1):S34-37.
43. MUIZELAAR JP, WEI EP, KONTOS HA, BECKER DP. Cerebral blood flow is regulated by changes in blood pressare and blood viscosità alike. Stroke 1986;17:44-48.
44. SINOR AD, GREENBERG DA. Erythropoietin protects cultured cortical neurons, but not astroglia, from hypoxia and AMPA toxicity. Neurosci Lett 2000;290:213-215.
45. GENC S, KURALAY F, GENC K, AKHISAROGLU M, FADILOGLU S, YORUKOGLU K, FADILOGLU M, GURE A. Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitrix oxide production. Neurosci Lett 2001;298:139-141.
46. SAKANAKA M, WEN TC, MATSUDA S, MASUDA S, MORISHITA E, NAGAO M. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998;95:4635-4640.